iTeos Therapeutics, Inc.
ITOS
$7.81
-$0.16-2.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 177.89% | -47.37% | -59.30% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 177.89% | -47.37% | -59.30% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 177.89% | -47.37% | -59.30% | -100.00% |
| SG&A Expenses | -7.41% | -2.56% | 1.09% | 6.24% | 13.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.22% | 19.85% | 14.28% | 16.88% | 16.07% |
| Operating Income | 11.45% | -6.35% | -58.87% | -119.21% | -832.44% |
| Income Before Tax | 9.82% | -10.37% | -93.08% | -284.39% | -979.94% |
| Income Tax Expenses | 180.01% | 289.51% | 156.31% | 223.81% | 38.90% |
| Earnings from Continuing Operations | 3.32% | -19.33% | -96.71% | -280.67% | -1,274.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.32% | -19.33% | -96.71% | -280.67% | -1,274.65% |
| EBIT | 11.45% | -6.35% | -58.87% | -119.21% | -832.44% |
| EBITDA | 11.68% | -6.15% | -59.17% | -120.56% | -872.29% |
| EPS Basic | 19.47% | -5.10% | -83.13% | -278.99% | -1,261.23% |
| Normalized Basic EPS | 24.97% | 2.61% | -79.75% | -283.40% | -971.54% |
| EPS Diluted | 19.54% | -5.07% | -80.11% | -265.14% | -1,418.25% |
| Normalized Diluted EPS | 24.97% | 2.61% | -76.20% | -268.71% | -1,070.52% |
| Average Basic Shares Outstanding | 18.21% | 13.14% | 8.12% | 3.13% | 0.53% |
| Average Diluted Shares Outstanding | 18.21% | 13.14% | 6.69% | 0.31% | -3.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |